Market Research Logo

Hematologic Malignancies Market Analysis by Type (Leukemia, Lymphoma, Multiple Myeloma), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy), And Segment Forecasts, 2014 - 2025

Hematologic Malignancies Market Analysis by Type (Leukemia, Lymphoma, Multiple Myeloma), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy), And Segment Forecasts, 2014 - 2025

The global hematologic malignancies market is estimated to reach USD 85.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing incidence of hematologic malignancies and presence of a strong product pipeline are estimated to boost the market. Moreover, increasing number of mergers and acquisitions are also expected to accelerate growth.

Furthermore, governments of developing countries are spending more on healthcare and on improving healthcare infrastructure. This is likely to reduce out-of-pocket expenditure for patients. which is considered as one of the major factors driving the hematologic malignancies market.

Recently it has been seen that the government sources are taking an initiative in funding the institutes for breakthrough oncology research. This is a major growth driver for the market as it will support the institutes to conduct their research on a larger-scale without any financial constraints. Federal government funding for research in oncology has led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancement in cancer research, more patients with cancer are being successfully treated. The increasing investment in cancer research is expected to boost the growth of market during forecast period

Further key findings from the report suggest:

  • Multiple myeloma is expected to be one of the fastest growing segments over the forecast period owing to strong pipeline of blockbuster products
  • Chronic myeloid leukemia was identified as the largest leukemia subtype in 2016 due to availability of large number of products and high number of target population
  • Chemotherapy held the largest share in 2016 on the basis of therapy due to its preference as first line of therapy and wide product range
  • Immunotherapy is anticipated to be the fastest growing segment and this can be attributed to lower adverse effects and higher efficiency
  • North America dominated the market in 2016 owing to local presence of key players and increasing number of mergers and acquisitions
  • Asia Pacific is expected to be the fastest growing region over the next decade with lucrative CAGR from 2017 to 2025 due to improving economic conditions and rising healthcare expenditure
  • Some of the key players are Pfizer, Inc.; F. Hoffmann-LA Roche Ltd; Sanofi; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited
  • Most of the key players are focusing on expanding their product portfolios, development of new treatment, and acquisitions.


Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Hematologic Malignancies Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.2 Market Driver Analysis
3.2.1 Growing Incidence of blood cancer
3.2.2 Increasing investment for cancer research
3.2.3 Strong product pipeline
3.2.4 Increasing Acquisition and Collaboration
3.3 Market restraint analysis
3.3.1 Reimbursement Policies
3.3.2 Large Capital Investment
3.4 Penetration & growth prospect mapping
3.5 Hematologic malignancies - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
Chapter 4 Hematologic Malignancies Market: Type Outlook
4.1 Hematologic malignancies market by type, movement analysis
4.2 Leukemia
• Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.1 Acute lymphocytic Leukemia
• Acute lymphocytic Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.2 Chronic lymphocytic Leukemia
• Chronic lymphocytic Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.3 Acute myeloid Leukemia
• Acute myeloid Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.4 Chronic myeloid Leukemia
• Chronic myeloid Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.3 Lymphoma
• Lymphoma Market estimates and forecast, 2014 - 2025 (USD Billion)
4.4 Multiple Myeloma
• Multiple myeloma Market estimates and forecast, 2014 - 2025 (USD Billion)
4.5 Others
• Others Market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 5 Hematologic Malignancies Market: Therapy Estimates & Trend Analysis
5.1 Hematologic malignancies market: Therapy movement analysis
5.2 Chemotherapy
• Chemotherapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.3 Radiotherapy
• Radiotherapy market estimates and forecast, 2013 - 2024 (USD Billion)
5.4 Immunotherapy
• Immunotherapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.5 Stem cell transplantation
• Stem cell transplantation market estimates and forecast, 2014 - 2025 (USD Billion)
5.6 Others
• Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 6 Hematologic Malignancies Market: Regional Outlook
6.1 Hematologic malignancies market share by region, 2015 & 2025 (USD Billion)
6.2 North America
6.2.1 U.S
6.2.1.1 U.S. hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.2.1.2 U.S. hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.2.2 Canada
6.2.2.1 Canada hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.2.2.2 Canada hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.3 Europe
6.3.1 UK
6.3.1.1 UK hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.3.1.2 UK hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.3.2 Germany
6.3.2.1 Germany hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.3.2.2 Germany hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.4 Asia Pacific
6.4.1 Japan
6.4.1.1 Japan hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.4.1.2 Japan hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.4.2 China
6.4.2.1 China hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.4.2.2 China hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.4.3 India
6.4.3.1 India hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.4.3.2 India hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.5 Latin America
6.5.1 Brazil
6.5.1.1 Brazil hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.5.1.2 Brazil hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.5.2 Mexico
6.5.2.1 Mexico hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.5.2.2 Mexico hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.6 MEA
6.6.1 South Africa
6.6.1.1 South Africa hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.6.1.2 South Africa hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.2.1 Company Profiles
7.2.2 Pfizer Inc
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.3 F. Hoffmann-LA Roche Ltd
• Company overview
• Financial Performance
• Product benchmarking
• Strategic initiatives
7.2.4 Sanofi
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.5 Bristol-Myers Squibb Company
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.6 AbbVie Inc
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.7 Novartis AG
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.8 GlaxoSmithKline PLC
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.9 Celgene Corporation
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
7.2.10 Johnson & Johnson Services, Inc
• Company overview
• Financial performance
• Product benchmarking
• Strategic Initiatives
7.2.11 Takeda Pharmaceutical Company
• Company overview
• Financial performance
• Product benchmarking
• Strategic Initiatives
List of Tables
TABLE 1 Country share estimation
TABLE 2 North America hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 3 North America hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 4 North America hematologic malignancies market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
TABLE 5 U.S. hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 6 U.S. hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 7 U.S. hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 8 Canada hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 9 Canada hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 10 Canada hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 11 Europe hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 12 Europe hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 13 Europe hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 14 U.K hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 15 U.K hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 16 U.K hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 17 Germany hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 18 Germany hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 19 Germany hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 20 Asia Pacific hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 21 Asia Pacific hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 22 Asia Pacific hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 23 Japan hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 24 Japan hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 25 Japan hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 26 China hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 27 China hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 28 China hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 29 India hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 30 India hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 31 India hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 32 Latin America hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 33 Latin America hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 34 Latin America hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 35 Brazil hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 36 Brazil hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 37 Brazil hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 38 Mexico hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 39 Mexico hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 40 Mexico hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 41 MEA hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 42 MEA hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 43 MEA hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 44 South Africa hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 45 South Africa hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 46 South Africa hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary
FIG. 6 Market trends &outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Estimated New Cases of Blood Cancer in U.S. (2017)
FIG. 10 Acquisitions and Collaborations according to Therapeutic area
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 National Reimbursement Status
FIG. 13 Penetration & growth prospect mapping
FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 Hematologic malignancies market type outlook
FIG. 17 Hematologic malignancies market: Type movement analysis
FIG. 18 Global Leukemia market, 2014 - 2025 (USD Billion)
FIG. 19 Global Acute lymphocytic leukemia market, 2014 - 2025 (USD Billion)
FIG. 20 Global Chronic lymphocytic leukemia market, 2014 - 2025 (USD Billion)
FIG. 21 Global Acute myeloid leukemia market, 2014 - 2025 (USD Billion)
FIG. 22 Global Chronic myeloid leukemia market, 2014 - 2025 (USD Billion)
FIG. 23 Global Lymphoma market, 2014 - 2025 (USD Billion)
FIG. 24 Global Multiple myeloma market, 2014 - 2025 (USD Billion)
FIG. 25 Global Others market, 2014 - 2025 (USD Billion)
FIG. 26 Hematologic malignancies market therapy outlook key takeaways
FIG. 27 Hematologic malignancies market: Leukemia movement analysis
FIG. 28 Global Chemotherapy market, 2014 - 2025 (USD Billion)
FIG. 29 Global Radiotherapy market, 2014 - 2025 (USD Billion)
FIG. 30 Global Immunotherapy market, 2014 - 2025 (USD Billion)
FIG. 31 Global Stem cell transplantation market, 2014 - 2025 (USD Billion)
FIG. 32 Global others market, 2014 - 2025 (USD Billion)
FIG. 33 Regional market place: Key takeaways
FIG. 34 Regional outlook, 2015 & 2025
FIG. 35 North America hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 36 U.S. hematologic malignancies market, 2013 - 2024 (USD Billion)
FIG. 37 Canada hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 38 Europe hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 39 UK hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 40 Germany hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 41 Asia Pacific hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 42 Japan hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 43 China hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 44 India hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 45 Latin America hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 46 Brazil hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 47 Mexico hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 48 MEA hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 49 South Africa hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 50 Strategy framework
FIG. 51 Participant categorization

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report